{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T19:46:23Z","timestamp":1788205583959,"version":"build-2803163510"},"reference-count":44,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T00:00:00Z","timestamp":1677283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Background: A specific, cost-effective triage test for minor cytological abnormalities is essential for cervical cancer screening among younger women to reduce overmanagement and unnecessary healthcare utilization. We compared the triage performance of one 13-type human papillomavirus (HPV) DNA test and one 5-type HPV mRNA test. Methods: We included 4115 women aged 25\u201333 years with a screening result of atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesions (LSIL) recorded in the Norwegian Cancer Registry during 2005\u20132010. According to Norwegian guidelines, these women went to triage (HPV testing and repeat cytology: 2556 were tested with the Hybrid Capture 2 HPV DNA test, which detects the HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68; and 1559 were tested with the PreTect HPV-Proofer HPV mRNA test, which detects HPV types 16, 18, 31, 33, and 45). Women were followed through December 2013. Results: HPV positivity rates at triage were 52.8% and 23.3% among DNA- and mRNA-tested women (p &lt; 0.001), respectively. Referral rates for colposcopy and biopsy and repeat testing (HPV + cytology) after triage were significantly higher among DNA-tested (24.9% and 27.9%) compared to mRNA-tested women (18.3% and 5.1%), as were cervical intraepithelial neoplasia grade 3 or worse (CIN3+) detection rates (13.1% vs. 8.3%; p &lt; 0.001). Ten cancer cases were diagnosed during follow-up; eight were in DNA-tested women. Conclusion: We observed significantly higher referral rates and CIN3+ detection rates in young women with ASC-US\/LSIL when the HPV DNA test was used at triage. The mRNA test was as functional in cancer prevention, with considerably less healthcare utilization.<\/jats:p>","DOI":"10.3390\/ijerph20054119","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T02:22:16Z","timestamp":1677464536000},"page":"4119","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["13-Type HPV DNA Test versus 5-Type HPV mRNA Test in Triage of Women Aged 25\u201333 Years with Minor Cytological Abnormalities\u20136 Years of Follow-Up"],"prefix":"10.3390","volume":"20","author":[{"given":"Amir","family":"Rad","sequence":"first","affiliation":[{"name":"Department of Community Medicine & Department of Clinical Medicine, UiT The Arctic University of Norway, 9037 Troms\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8250-3992","authenticated-orcid":false,"given":"Sveinung Wergeland","family":"S\u00f8rbye","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital of North Norway, 9019 Troms\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3717-8323","authenticated-orcid":false,"given":"Tormod","family":"Brenn","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, UiT The Arctic University of Norway, 9037 Troms\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2252-3171","authenticated-orcid":false,"given":"Sweta","family":"Tiwari","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, UiT The Arctic University of Norway, 9037 Troms\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8532-6573","authenticated-orcid":false,"given":"Maja-Lisa","family":"L\u00f8chen","sequence":"additional","affiliation":[{"name":"Department of Community Medicine & Department of Clinical Medicine, UiT The Arctic University of Norway, 9037 Troms\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9875-4991","authenticated-orcid":false,"given":"Finn Egil","family":"Skjeldestad","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, UiT The Arctic University of Norway, 9037 Troms\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejca.2019.12.013","article-title":"Effect of organised cervical cancer screening on cervical cancer mortality in Europe: A systematic review","volume":"127","author":"Jansen","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_2","first-page":"CD008587","article-title":"Cytology versus HPV testing for cervical cancer screening in the general population","volume":"8","author":"Koliopoulos","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ypmed.2018.12.021","article-title":"HPV-based cervical screening: Rationale, expectations and future perspectives of the new Dutch screening programme","volume":"119","author":"Polman","year":"2018","journal-title":"Prev. Med."},{"key":"ref_4","unstructured":"England, P.H. (2022, December 05). Cervical Screening: Programme Overview, Available online: https:\/\/www.gov.uk\/guidance\/cervical-screening-programme-overview."},{"key":"ref_5","unstructured":"(2022, December 05). National Cervical Screening Program: Guidelines for the Management of Screen-Detected Abnormalities, Screening in Specific Populations and Investigation of Abnormal Vaginal Bleeding. Available online: https:\/\/wiki.cancer.org.au\/australiawiki\/images\/a\/ad\/National_Cervical_Screening_Program_guidelines_long-form_PDF.pdf."},{"key":"ref_6","unstructured":"WHO (2021). WHO Guideline for Screening and Treatment of Cervical Pre-Cancer Lesions for Cervical Cancer Prevention, WHO. [2nd ed.]."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pvr.2015.06.006","article-title":"European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination","volume":"1","author":"Arbyn","year":"2015","journal-title":"Papillomavirus Res."},{"key":"ref_8","unstructured":"Institution, T.P.H. (2022, December 05). Turkey Cancer Control Programme. Available online: https:\/\/www.iccp-portal.org\/system\/files\/plans\/Turkiye_Kanser_Kontrol_Program_English.pdf."},{"key":"ref_9","unstructured":"Socialstyrelsen (2022, December 05). Senaste Versionen av HSLF-FS 2019:14 Socialstyrelsens F\u00f6reskrifter Och Allm\u00e4nna R\u00e5d om Villkor f\u00f6r Avgiftsfri Screening. Available online: https:\/\/www.socialstyrelsen.se\/kunskapsstod-och-regler\/regler-och-riktlinjer\/foreskrifter-och-allmanna-rad\/konsoliderade-foreskrifter\/201914-om-villkor-for-avgiftsfri-screening\/."},{"key":"ref_10","unstructured":"Norway, C.R.O. (2022, December 05). HPV I Prim\u00e6rscreening. Cancer Registry of Norway. Available online: https:\/\/www.kreftregisteret.no\/en\/screening\/cervix\/Helsepersonell\/screeningstrategi-og-nasjonale-retningslinjer\/hpv-i-primarscreening\/."},{"key":"ref_11","unstructured":"Norway, T.C.R.O. (2022, December 05). Primary HPV Test\u2014Now also for Women Under 34. Available online: https:\/\/www.kreftregisteret.no\/screening\/livmorhalsprogrammet\/hpv\/."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1086\/657321","article-title":"Cervical Human Papillomavirus Prevalence in 5 Continents: Meta-Analysis of 1 Million Women with Normal Cytological Findings","volume":"202","author":"Bruni","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/AOG.0b013e31818c9222","article-title":"Risks for Cervical Intraepithelial Neoplasia 3 Among Adolescents and Young Women with Abnormal Cytology","volume":"112","author":"Moscicki","year":"2008","journal-title":"Obstet. Gynecol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1097\/AOG.0b013e3181fe777f","article-title":"Rate of and Risks for Regression of Cervical Intraepithelial Neoplasia 2 in Adolescents and Young Women","volume":"116","author":"Moscicki","year":"2010","journal-title":"Obstet. Gynecol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ygyno.2005.07.108","article-title":"Human papillomavirus E6\/E7 mRNA expression in women younger than 30 years of age","volume":"100","author":"Molden","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJM199802123380703","article-title":"Natural History of Cervicovaginal Papillomavirus Infection in Young Women","volume":"338","author":"Ho","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_17","unstructured":"Boardman, L.A., and Robison, K. (2013). Obstetrics and Gynecology Clinics of North America, W.B. Saunders Ltd."},{"key":"ref_18","unstructured":"Enges\u00e6ter, B.L.G., Skare, G.B., and Trop\u00e9, A. (2021). \u00c5rsrapport 2021\u2014Screeningaktivitet og Resultater fra Livmorhalsprogrammet, Cancer Registry of Norway."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0301-2115(97)00171-1","article-title":"Comparison of the risks of cytologic surveillance of women with atypical cells or low-grade abnormalities on cervical smear: Review of the literature","volume":"76","author":"Baldauf","year":"1998","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_20","first-page":"728","article-title":"Spontaneous regression of low-grade cervical intraepithelial lesions is positively improved by topical bovine colostrum preparations (GINEDIE\u00ae). A multicentre, observational, Italian pilot study","volume":"18","author":"Stefani","year":"2014","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_21","first-page":"444","article-title":"Management of low-grade cervical cytology in young women. Cohort study from Denmark","volume":"60","author":"Thamsborg","year":"2020","journal-title":"Acta Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1097\/LGT.0b013e318285423c","article-title":"Benchmarking CIN 3+ Risk as the Basis for Incorporating HPV and Pap Cotesting into Cervical Screening and Management Guidelines","volume":"17","author":"Katki","year":"2013","journal-title":"J. Low. Genit. Tract Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/ijc.27713","article-title":"Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe","volume":"132","author":"Tjalma","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"S\u00f8rbye, S.W., Fismen, S., Gutteberg, T.J., Mortensen, E.S., and Skjeldestad, F.E. (2014). HPV mRNA Is More Specific than HPV DNA in Triage of Women with Minor Cervical Lesions. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0112934"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000381842","article-title":"The Pap Test and Bethesda 2014. \u201cThe reports of my demise have been greatly exaggerated\u201d. (after a quotation from Mark Twain)","volume":"59","author":"Nayar","year":"2015","journal-title":"Acta. Cytol."},{"key":"ref_26","unstructured":"WHO (2006). Comprehensive Cervical Cancer Control: A Guide to Essential Practice, WHO."},{"key":"ref_27","unstructured":"QIAGEN (2022, December 05). Digene Specimen Transport Medium. Available online: https:\/\/www.qiagen.com\/de\/products\/diagnostics-and-clinical-research\/sexual-reproductive-health\/cervical-cancer-screening\/digene-specimen-transport-medium."},{"key":"ref_28","unstructured":"PreTect, T.M. (2022, December 05). Available online: https:\/\/www.pretect.no\/products\/pretecttm."},{"key":"ref_29","unstructured":"QIAGEN (2022, December 05). Digene HC2 HPV DNA Test. Available online: https:\/\/www.qiagen.com\/us\/products\/diagnostics-and-clinical-research\/sexual-reproductive-health\/cervical-cancer-screening\/digene-hc2-hpv-dna-test."},{"key":"ref_30","unstructured":"PreTect (2022, December 05). PRETECT HPV-PROOFER. Available online: https:\/\/www.pretect.no\/products\/pretecthpvproofermoreinformation."},{"key":"ref_31","unstructured":"PreTect (2022, December 05). NASBA\u2014NUCLEIC ACID SEQUENCE BASED AMPLIFICATION. Available online: https:\/\/www.pretect.no\/nasba."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1582-4934.2008.00631.x","article-title":"Triage of women with equivocal or low-grade cervical cytology results: A meta-analysis of the HPV test positivity rate","volume":"13","author":"Arbyn","year":"2009","journal-title":"J. Cell Mol. Med."},{"key":"ref_33","first-page":"e0275858","article-title":"Triage of low-grade squamous intraepithelial lesions using human papillomavirus messenger ribonucleic acid tests\u2014A prospective population-based register study","volume":"17","author":"Reinholdt","year":"2019","journal-title":"Acta Obstet. Gynecol.Scand."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Westre, B., Giske, A., Guttormsen, H., S\u00f8rbye, S., and Skjeldestad, F.E. (2016). 5-type HPV mRNA versus 14-type HPV DNA test: Test performance, over-diagnosis and overtreatment in triage of women with minor cervical lesions. BMC Clin. Pathol., 16.","DOI":"10.1186\/s12907-016-0032-x"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/ijc.30104","article-title":"Human papillomavirus mRNA and DNA testing in women with atypical squamous cells of undetermined significance: A prospective cohort study","volume":"139","author":"Thomsen","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1097\/LGT.0b013e318285437b","article-title":"Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive","volume":"17","author":"Katki","year":"2013","journal-title":"J. Low Genit. Tract. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/LGT.0000000000000529","article-title":"Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines","volume":"24","author":"Egemen","year":"2020","journal-title":"J. Low Genit. Tract. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/1471-0528.14135","article-title":"Using novel biomarkers to triage young adult women with minor cervical lesions: A cost-effectiveness analysis","volume":"124","author":"Pedersen","year":"2017","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"key":"ref_39","first-page":"1510","article-title":"How many Human Papillomavirus types do we need to screen for?","volume":"22","author":"Sundstrom","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_40","unstructured":"Norway, C.R.O. (2022, December 05). Cervical Cancer Screening Programme. Available online: https:\/\/www.kreftregisteret.no\/en\/screening\/cervix\/org\/."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1097\/AOG.0000000000001777","article-title":"Adverse Pregnancy Outcomes After Treatment for Cervical Intraepithelial Neoplasia","volume":"128","author":"Skare","year":"2016","journal-title":"Obstet. Gynecol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/AOG.0b013e31818f5008","article-title":"Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2","volume":"113","author":"Castle","year":"2009","journal-title":"Obstet. Gynecol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(08)70103-7","article-title":"Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: A retrospective cohort study","volume":"9","author":"McCredie","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(09)70360-2","article-title":"New Technologies for Cervical Cancer screening Working. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: A randomised controlled trial","volume":"11","author":"Ronco","year":"2010","journal-title":"Lancet Oncol."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/20\/5\/4119\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:42:21Z","timestamp":1760121741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/20\/5\/4119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,25]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["ijerph20054119"],"URL":"https:\/\/doi.org\/10.3390\/ijerph20054119","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,25]]}}}